IP Library › Granted Patent US 11,530,247
Granted Patent B2
US 11,530,247 · App. 16/618,233 · Granted Dec 20, 2022

Single-chain TNF receptor 2 agonist fusion proteins

Inventors: David C Foster (Euless, TX); Lutz B Giebel (San Mateo, CA); Leonard G Presta (San Francisco, CA)
Assignee: RELINIA, INC.
C07K14/525A61P29/00A61K38/00A61K39/00C07K16/46C07K19/00C07K2319/02C07K2319/30C07K2319/50C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,530,247
App. No.
16/618,233
Granted
Dec 20, 2022
Kind
B2
Abstract

This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.

Claims (20)

1. A fusion protein comprising SEQ ID NO: 31, SEQ ID NO:32, SEQ ID NO:34 or SEQ ID NO:35.

2. A fusion protein comprising a sequence selected from the group consisting of SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119 and SEQ ID NO:120.

3. A pharmaceutical composition comprising the fusion protein of claim 2 .

4. The pharmaceutical composition of claim 3 , wherein the fusion protein comprises the sequence of SEQ ID NO:107.

5. The pharmaceutical composition of claim 3 , wherein the fusion protein comprises the sequence of SEQ ID NO:110.

6. The pharmaceutical composition of claim 3 , wherein the fusion protein comprises the sequence of SEQ ID NO:113.

7. The pharmaceutical composition of claim 3 , wherein the fusion protein comprises the sequence of SEQ ID NO:115.

8. The pharmaceutical composition of claim 3 , wherein the fusion protein consists of the sequence of SEQ ID NO:107.

9. The pharmaceutical composition of claim 3 , wherein the fusion protein consists of the sequence of SEQ ID NO:110.

10. The pharmaceutical composition of claim 3 , wherein the fusion protein consists of the sequence of SEQ ID NO:113.

11. The pharmaceutical composition of claim 3 , wherein the fusion protein consists of the sequence of SEQ ID NO:115.

12. A dimerized polypeptide comprising two fusion proteins according to claim 2 .

13. The fusion protein according to claim 2 , wherein the fusion protein comprises the sequence of SEQ ID NO: 107.

14. The fusion protein according to claim 2 , wherein the fusion protein comprises the sequence of SEQ ID NO: 110.

15. The fusion protein according to claim 2 , wherein the fusion protein comprises the sequence of SEQ ID NO: 113.

16. The fusion protein according to claim 2 , wherein the fusion protein comprises the sequence of SEQ ID NO: 115.

17. The fusion protein according to claim 2 , wherein the fusion protein consists of the sequence of SEQ ID NO: 107.

18. The fusion protein according to claim 2 , wherein the fusion protein consists of the sequence of SEQ ID NO: 110.

19. The fusion protein according to claim 2 , wherein the fusion protein consists of the sequence of SEQ ID NO: 113.

20. The fusion protein according to claim 2 , wherein the fusion protein consists of the sequence of SEQ ID NO: 115.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: FOSTER, DAVID C.; GIEBEL, LUTZ B.; PRESTA, LEONARD G.
To: RELINIA, INC.
Reel/Frame 061383/0411 →
Continuity (2)
Provisional Application 62515643 · Jun 6, 2017
Related Publication 20200369739A1 · Nov 26, 2020
Cited By (1)
US 12,410,223